

OFFICIALLY LICENSED

# BEST OF ASCO®

## 2016 ANNUAL MEETING Ciudad de México

OFFICIALLY LICENSED

### BEST OF ASCO

2016 ANNUAL MEETING



**MPR**

MEDICAL PHARMA RESEARCH LATAM



**JULIO  
14 Y 15  
DEL 2016  
CIUDAD DE MÉXICO**

Auditorio INMEGEN  
del Instituto Nacional  
de Medicina Genómica

5350-7256

[oncologia@medicalrp.us](mailto:oncologia@medicalrp.us)

[www.medicalrp.us](http://www.medicalrp.us)

[www.congresosmpr.com](http://www.congresosmpr.com)

## Programa Final Auditorio del INMEGEN



## Comité Científico:

Presidente: Dra. Aura Erazo Valle  
Miembros : Dra. Guadalupe Cervantes S.  
Dra. Laura Torrecillas T.



## Coordinadores de Módulo

Dr. Campos Saúl	COE Issemym
Dra. Cervantes S. Guadalupe	CMN 20 de Nov.
Dr. Clemenceau Rene	Hosp. Ángeles
Dra. Demichelis Roberta	INCMNSZ
Dr. Escobar Gómez Mario	Hosp. Gral. de México
Dra. Gallardo Dolores	INCan
Dr. López Sachiñas Francisco	Hosp Naval
Dr. Robles A. Jorge	Pemex Sur
Dr. Silva Alejandro	CMN Siglo XXI
Dra. Torrecillas Laura	CMN 20 de Nov.
Dr. Villalobos Ricardo	CMN La Raza

## Ponentes

Dr. Aldaco Fernando	CMN 20 de Nov
Dra. Arce Claudia	INCan
Dr. Borunda Karim	Siglo XXI
Dra. Bourlon Ma. Teresa	INCMNSZ
Dra. Cabrera Paula	INCan
Dra. Candelaria Myrna	INCan
Dra. Cortes Patricia	CMN 20 de Nov.
Dra. Chávez Hdez. Nora	IMSS
Dra. Ma. Isabel Enriquez A.	ISSSTE León, Gto.
Dra. García Montes Vanessa	Hosp. Gral de México
Dra. Garnica Jaliffe Georgina	Hosp. Gral de México
Dra. Gómez García Eva Ma.	COE Issemym
Dr. Juárez Alejandro	CMN 20 de Nov.
Dr. Lacayo Dennis	INCMNSZ
Dr. Mainero R. Fernando	Gineco 4
Dr. Matus Santos Juan Antonio	INCan
Dr. Orta Cortes David	Hosp Naval
Dr. Oñate Ocaña Luis	INCan
Dr. Pérez Mario	PEMEX Sur
Dra. Pérez Perla	CMN 20 de Nov.
Dr. Pimentel Rentería Alberto	CMN Siglo XXI
Dra. Portela Gradel	PEMEX Sur
Dr. Ramírez Martínez Pablo	COE Issemym
Dr. Terrazas Ricardo	INCMNSZ
Dr. Toriz Hernandez Adalberto	Hosp Naval
Dra. Torrecillas Torres Laura	CMN 20 de Nov

# Jueves 14 de Julio

08:AM

## REGISTRO

8:50	<b>INAUGURACIÓN</b> Presidium: Dra Erazo Valle, Dr Carlos Aranda, Dra Cervantes Sanchez, Dra Laura Torrecillas, Dr Pedro Escudero de los Rios, Lic. David Erazo, Lic. Jorge Garcia,		Dr. Pabel Miranda Maestro de Ceremonias
9:10	Breast Cancer	A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.	Dra. Paula Cabrera INCan
9:20		Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA).	Dra. Claudia Arce INCan
9:30		PALOMA-2: Primary results from a phase 3 trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2- advanced breast cancer (ABC).	
9:40		Pathologic complete response rates after neoadjuvant trastuzumab emtansine (T-DM1) + pertuzumab vs docetaxel + carboplatin + trastuzumab + pertuzumab treatment in patients with HER2-positive early breast cancer (KRISTINE).	Dr Fernando Aldaco CMN 20 de Nov.
9:50		Mesa Redonda	Dra. Guadalupe Cervantes CMN 20 de Nov
10:00		Cáncer de Mama HER2 +, la nueva Era en el tratamiento	Dr. Antonio Matus INCan
10:50	COFFEE BREAK		
11:20	GI Colorectal	Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).	Dra. Laura Torrecillas CMN 20 de Nov.
11:30		The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers.	Dra. Nora Chávez IMSS
11:40		FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized study—Prodiges 14 – Accord 21 (METHEP-2), a UNICANCER GI trial.	
11:50		Preguntas y Respuestas	Dra. Laura Torrecillas CMN 20 de Nov
12:00		Cabazitaxel en Cancer de Próstata Metastásico Resistente a la Castración	Dra. Perla Pérez CMN 20 de Nov.

12:50	GI Non Colorectal	Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)- CALGB 80802 (Alliance).	Dr. Alberto Pimentel CMN Siglo XXI
13:00		A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study.	
13:10		ESPAC-4: A multicenter, international, open label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP), versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.	Dr. Karim Borunda CMN Siglo XXI
13:20		Mesa Redonda	Dr Alejandro Silva CMN Siglo XXI
13:30	Linfoma	Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study.	Dra Roberta Demichelis INCMNSZ
13:40		A phase 2 trial of ABVD followed by brentuximab vedotin consolidation in limited stage non-bulky Hodgkin lymphoma.	Dr. Dennis Lacayo INCMNSZ
13:50		Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase 2 study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial).	Dr. Ricardo Terrazas INCMNSZ
14:00		Mesa Redonda	Dra. Roberta Demichelis INCMNSZ
14:10	Patient & Survivor care	A URCC NCORP nationwide randomized controlled trial investigating the effect of exercise on chemotherapy-induced peripheral neuropathy in 314 cancer patients.	Dra. Myrna Candelaria INCan
14:20		Placebo-controlled phase III study comparing dexamethasone on day1 to on day1-3 with NK1 receptor antagonist and palonosetron in high emetogenic chemotherapy.	Dra. Ma. Teresa Bourlon INCan
14:30			Mesa Redonda

— OFFICIALLY LICENSED —

# BEST OF ASCO®

## 2016 ANNUAL MEETING

# Viernes 15 de Julio

7:30	REGISTRO		
8:30	Triple Negative / Local Therapy	Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer.	Dr. Juan Antonio Matus INCan
8:40		Ten-year survival results of ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node (Alliance).	Dr. Fernando Mainero Hosp Gineco 4 IMSS
8:50		Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.	
9:00		Mesa Redonda	Dr Ricardo Villalobos CMN LA Raza
9:10	HER 2	Nuevos horizontes en el tratamiento del Cáncer de mama metastasico HR + HER2 -	Dra. Guadalupe Cervantes CMN 20 de Noviembre
10:00	H & N	Abstract 6089 Response to lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC): Updated results from SELECT.	Dr Alejandro Juárez CMN 20 de Nov. ISSSTE
10:10		Induction taxotere platinum 5-FU (TPF) followed by cetuximab-radiotherapy versus concurrent chemo-radiotherapy in patients with N2b-N3 (non operated Stage III-IV) squamous cell cancer of the head and neck (SCCHN): Results of the GORTEC 2007-02 phase III randomized trial.	Dr. Mario Pérez PEMEX SUR
10:20		Nivolumab versus therapy of investigator's choice (IC) for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.	Dra Gredel Portela PEMEX Sur
10:30		Mesa Redonda	Dr Jorge Robles PEMEX
10:40	COFFEE BREAK		
11:10	G U	Cabazitaxel vs docetaxel in chemotherapy-naïve (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A 3-arm phase III study (FIRSTANA).	Dr. Adalberto Toriz Hosp Naval
11:20		Phase III non-inferiority study of cabazitaxel (C) 20 mg/m <sup>2</sup> (C20) versus 25 mg/m <sup>2</sup> (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).	
11:30		Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).	Dr. David Orta Hosp Naval
11:40		Mesa Redonda	Dr. Francisco López Hosp. Naval
11:50		Bevacizumab, 10 años, cambiando historias	Dra. Ma. Isabel Enriquez ISSSTE León Gto.

12:40	Gineco	Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis.	Dra. Dolores Gallardo INCan
12:50		OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) vs. intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC).	Dra. Patricia Cortes CMN 20 de Nov.
13:00		Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG Symptom Benefit Study (SBS).	Dr. Luis Oñate INCan
13:10		Mesa Redonda	Dra. Dolores Gallardo INCAN
13:20	Melanoma	Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067).	Dra. Eva Gómez COE ISSEMYM
13:30		Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006.	Dr. Pablo Ramirez COE ISSEMYM
13:40		Mesa Redonda	Dr. Saúl Campos COEI
13:50	Pulmón	Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC).	Dra. Georgina Garnica Hosp. Gral de México
14:00		Primary analysis for alectinib versus crizotinib in ALK-inhibitor naïve ALK positive non-small cell lung cancer (ALK+ NSCLC) in randomized open-label phase III trial (J-ALEX study).	Dra. Vannesa García Hosp. Gral de México
14:10		Mesa Redonda	Dr. Mario Escobar Hosp Gral de México
14:20	Clausura		

— OFFICIALLY LICENSED —

# BEST OF ASCO®

## 2016 ANNUAL MEETING

Esta actividad académica ha sido reconocida y avalada por la **SMeO** y por el **Consejo Mexicano de Oncología** quien ha otorgado 5 puntos para Re Certificación a los asistentes.

La Constancia de Asistencia se entregará **UNICAMENTE** vía electrónica, (una vez que se haya respondido la encuesta de evaluación que le llegará vía: Survey Monkey ) a los Asistentes registrados durante el evento.

Agradeceremos verificar su nombre, apellidos / email directamente en el Mostrador de Registro. (cualquier aclaración deberá ser hecha, a más tardar, hasta un mes después del evento: [oncologia@medicalrp.us](mailto:oncologia@medicalrp.us))

